TrialNature medicine2025

Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial.

Matthew D Galsky et al.PubMed ↗Publisher ↗

No numbers read from the abstract.